irinotecan

(redirected from Camptosar)

irinotecan

A topoisomerase-1 inhibitor and semisynthetic analogue of the natural alkaloid camptothecin, which is activated by hydrolysis in vivo to an active metabolit, SN-38, and inactivated by glucuronidation with uridine diphosphate glucoronosyltransferase 1A1 (UGT1A1). It was FDA-approved for managing colorectal carcinoma in 1994. 

Adverse effects
Severe diarrhoea, possibly leading to dehydration, requiring aggressive antidiarrhoeal management with loperamide or Lomotil; immunosuppression with severe neutropaenia; functional overdose in patients who under-express UGT1A1 and cannot clear irinotecan as quickly (e.g., those with Gilbert syndrome as normal patients).
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.

irinotecan

An anticancer drug used to treat widespread secondary cancer of the colon or rectum. A brand name is Campto.
Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005
References in periodicals archive ?
Lexi Pharma team members have collectively filed 15 New Drug Applications and have been involved in the development and launch of successfully marketed products including: Byetta, Bydureon, Camptosar, Dacogen, Ellence, Emcyt, Erbitux, Folotyn, Panretin, Symlin, Sutent, Targretin, Vidaza, Velcade, and Zarnestra.
Then, a combination of leucovorin (Leucovorin Atafarm, Novartis)/fluorouracil (5-florourasil, Sandoz)/irinotecan (Camptosar, Pfizer) (Folfiri) was administered.
Recent pharmacokinetic (PK) data from its ongoing Phase 1 clinical study of IT-141 showed successful delivery of SN-38 far in excess of both Pfizer's Camptosar (irinotecan) and Merrimack's Onivyde (liposomal irinotecan), the latter of which was acquired by Ipsen in early 2017.
[13] Camptosar [prescribing information], 2017, http://labeling.pfizer .com/ShowLabeling.aspx?id=533.
Irinotecan is (CPT-11) activated by hydrolysis to SN-38, an inhibitor of (Camptosar) topoisomerase I and, thus, blocks replication and transcription.
Two synthetic forms, marketed as Camptosar and Hycamtin, are used in chemotherapy treatments today.
In 2000, irinotecan (Camptosar, Pfizer) given with bolus 5-FU and leucovorin injection (IFL regimen) was shown to improve median overall survival in previously untreated patients with metastatic colorectal cancer from 12.6 to 14.8 months versus 5-FU and leucovorin alone.
Modern pharmacology doesn't resign itself to the inevitability of side effects; it tracks them to the molecular variations that make some people allergic to aspirin, for example, and others unable to tolerate Camptosar, a powerful cancer drug.
* Irinotecan (Camptosar): This drug is often combined with 5-FU and leucovorin in a regimen called FOLFIRI.
TPMT ** Tabloid, [30] thioguanine (GlaxoSmithKine) DPD ** Xeloda, [31] capecitabine (Hoffman La Roche Inc.) ER-PGR ** Aromasin, [32] exemestane (Pfizer) G6PD ** Elitek, [33] rasburicase (Sanofi- synthelabo Inc.) ER * Nolvadex, [34] tamoxifen (AstraZeneca) ER * Arimidex, [35] anastrozole (AstraZeneca) ER ** Faslodex, [36] fulvestrant (AstraZeneca) UGT1A1 ** Camptosar, [37] irinotecan (Pfizer) ERCC1 * Camptosar, [38] irinotecan (Pfizer) tpmt * Platinol, [39] cisplatin, (Bristol-Myers Squibb Company) tpmt ** Tabloid, [40] thioguanine (GlaxoSmithKline) CDK 4 and 6 * Palbociclib, PD- [41] 0332991 (Pfizer) * This biomarkers are used for diagnostic and prognostic purposes to determine the proper cause of treatment (investigational diagnostics and/or drugs).
A case in point, they say, is Pfizer Inc.'s Camptosar (irinotecan hydrochloride), an injectable drug used to treat patients with colorectal cancer.
Comments: Revenues in the quarter were boosted by $5.2 billion, or 44%, due to legacy Wyeth products, and negatively impacted by $458 million, or 4%, due to legacy Pfizer products, including the loss of exclusivity of Lipitor in Canada and Spain, as well as Camptosar in Europe.